tirzepatide going off market FDA reconsidering its decision to take its drug shortage list Tirzepatide Statistics 2026: Mounjaro &

Monitoring Mental Health During Treatment Initial Assessment and Regular Monitoring When it comes to managing mental health risks associated with semaglutide and tirzepatide, careful monitoring is a must

Part 2 of ESSENCE is an open-label extension that will follow patients for up to five years, monitoring endpoints including cirrhosis-free survival, and is due to generate results in 2029

The longer you are on tirzepatide, the less likely GI-mediated dehydration becomes a significant concern

Hypoglycemia Increased heart rate Potential pancreatitis Gallbladder issues Acute kidney injury Risk of thyroid tumors It is recommended that patients be monitored for these risks, especially those with a history of thyroid disease